Hormonal
GLP-1 receptor agonists (specifically liraglutide and semaglutide) produce the greatest weight loss among anti-diabetic medications, with effects classified as strong (>5% reduction), whereas DPP-4 inhibitors and alpha-glucosidase inhibitors (acarbose) produce only mild or neutral effects.
If you have Type 2 Diabetes and struggle with weight loss, GLP-1 receptor agonists (like liraglutide or semaglutide) are currently the most effective pharmacological option for reducing body weight, significantly outperforming older drugs like DPP-4 inhibitors or acarbose. While these drugs may cause initial gastrointestinal side effects, their ability to produce strong weight loss (>5%) makes them a superior choice for managing obesity in diabetic patients compared to weight-neutral or weight-gain-inducing alternatives like sulfonylureas or insulin.
some glucagon-like peptide-1 (GLP-1) receptor agonists had the greatest impact on weight loss. Dipeptidyl peptidase 4 (DPP-4) inhibitors showed a neutral or mild weight loss effect... Acarbose has mild weight loss effects and metformin and sodium-dependent glucose cotransporter proteins-2 (SGLT-2) inhibitors have modest weight loss effects
Why this rating
Based on a comprehensive review of multiple clinical trials and meta-analyses, though specific pooled effect sizes for GLP-1s are less detailed in the abstract than for metformin.
Source
A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications
Fatma Haddad et al. · Life · 2023
DOI 10.3390/life13041012
More from this paper
- Metformin produces moderate weight loss (3-5% reduction) in adults with T2DM or obesity, primarily by lowering hunger and reducing calorie intake, and can prevent weight gain associated with antipsychotic medications.Strong
- SGLT-2 inhibitors and DPP-4 inhibitors produce modest or neutral weight loss effects, respectively, making them less effective for weight management compared to GLP-1 agonists.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →